KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Common Equity (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Common Equity data on record, last reported at $1.2 billion in Q4 2025.

  • For Q4 2025, Common Equity rose 67.49% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $1.2 billion, up 67.49%, while the annual FY2025 figure was $1.2 billion, 67.49% up from the prior year.
  • Common Equity reached $1.2 billion in Q4 2025 per ACAD's latest filing, up from $917.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $1.2 billion in Q4 2025 and bottomed at $362.2 million in Q3 2023.
  • Average Common Equity over 5 years is $577.4 million, with a median of $528.8 million recorded in 2021.
  • Peak YoY movement for Common Equity: decreased 25.97% in 2022, then soared 69.72% in 2024.
  • A 5-year view of Common Equity shows it stood at $540.9 million in 2021, then fell by 25.97% to $400.4 million in 2022, then rose by 7.83% to $431.8 million in 2023, then skyrocketed by 69.72% to $732.8 million in 2024, then soared by 67.49% to $1.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $1.2 billion in Q4 2025, $917.3 million in Q3 2025, and $822.4 million in Q2 2025.